DiaMedica Therapeutics Inc.
NASDAQ:DMAC
4.25 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | DiaMedica Therapeutics Inc. |
Symbool | DMAC |
Munteenheid | USD |
Prijs | 4.25 |
Beurswaarde | 181,678,150 |
Dividendpercentage | 0% |
52-weken bereik | 2.12 - 4.95 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Dietrich John Pauls MBA |
Website | https://www.diamedica.com |
An error occurred while fetching data.
Over DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)